Tatva Chintan Pharma Chem Share Price Target 2026 Analyst Forecast Bull and Bear Case

Tatva Chintan Pharma Chem (NSE: TATVA) is a Green Chemistry and Specialty Chemicals company trading at Rs 1,186 with a market capitalisation of Rs 2,371 crore. Analysts have set the Tatva Chintan Pharma Chem share price target at Rs 1,400 for 2026, based on FY27 earnings projections and sector re-rating potential. This article covers the complete 2026 price forecast including sector tailwinds, key risks, and bull and bear scenarios.

Click Here – Get Free Investment Predictions

Tatva Chintan Pharma Chem Share Price Target 2026: Key Takeaways

• Tatva Chintan Pharma Chem share price target 2026: Rs 1,400 (20% upside from CMP Rs 1,186)
• Bull case: Rs 1,700 | Bear case: Rs 950
• Ticker: TATVA | Sector: Green Chemistry and Specialty Chemicals | MCap: Rs 2,371 crore
• 52W range: Rs 821 to Rs 1,946 | PE: 30x
• Key catalyst: Q4 FY26 results and FY27 earnings confirmation in 2026
• Key risk: FY27 earnings miss or FII outflows from Indian equities

Tatva Chintan Pharma Chem Company Overview

Tatva Chintan Pharma Chem (NSE: TATVA) is an Ankleshwar-based green chemistry company manufacturing phase transfer catalysts, quaternary ammonium compounds, ionic liquids, and SDAs for pharma, agrochemical, and polymer industries globally. At CMP Rs 1,186 against a 52 week range of Rs 821 to Rs 1,946, the stock trades at a meaningful discount to its 52 week high. Market capitalisation is Rs 2,371 crore with trailing PE of 30x. Compared to peers in green chemistry like Fine Organic and Aarti Industries, Tatva Chintan Pharma Chem is positioned as a potential re-rating candidate toward the Rs 1,400 price objective on FY27 earnings delivery.

Parameter	Value
NSE Ticker	TATVA
Sector	Green Chemistry and Specialty Chemicals
CMP (2026)	Rs 1,186
52 Week High	Rs 1,946
52 Week Low	Rs 821
Market Cap	Rs 2,371 crore
Trailing PE	30x
12-Month Analyst Target	Rs 1,400
Bull Case Target	Rs 1,700
Bear Case Target	Rs 950

Why Is the Tatva Chintan Pharma Chem Share Price Target Set at Rs 1,400 for 2026

FY27 Earnings Recovery and Revenue Acceleration

The Tatva Chintan Pharma Chem share price target of Rs 1,400 rests on analyst projections of 15 to 20 percent PAT growth in FY27. Q4 FY26 results released in 2026 confirming the earnings trajectory are the most direct catalyst for re-rating from CMP Rs 1,186.

Structural Sector Tailwinds in Green Chemistry and Specialty Chemicals

The Green Chemistry and Specialty Chemicals sector is expanding on the back of India’s domestic demand growth, PLI scheme support, and rising corporate investment. Tatva Chintan Pharma Chem’s position among peers in green chemistry like Fine Organic and Aarti Industries creates a structural growth runway. Sustained outperformance is one of the key conditions for the Rs 1,700 bull case to materialise.

RBI Rate Cut Cycle and Lower Cost of Capital

India’s RBI rate cut cycle in 2026 is reducing borrowing costs and stimulating end market demand. Lower interest costs improve Tatva Chintan Pharma Chem’s EPS trajectory, narrowing the gap between current earnings and the FY27 estimates that underpin the Rs 1,400 analyst consensus.

Union Budget 2026-27 Capex Push and Policy Support

Budget 2026-27’s Rs 11.21 lakh crore infrastructure capex and PLI scheme continuity create a favourable backdrop for Tatva Chintan Pharma Chem’s Green Chemistry and Specialty Chemicals operations, improving the probability of achieving the Rs 1,400 price objective through FY27 earnings delivery.

FII Flow Normalisation After the 2026 Tariff Shock

As global macro conditions normalise through 2026, FII flows into quality Indian equities are gradually recovering. At 30x PE, Tatva Chintan Pharma Chem is positioned as a beneficiary of institutional reallocation toward the Rs 1,700 bull case over the medium term.

Tatva Chintan Pharma Chem Share Price Targets: Short Term, 12 Month, and Long Term

Short Term Tatva Chintan Pharma Chem Share Price Target

Near-term support for Tatva Chintan Pharma Chem is anchored close to the 52 week low of Rs 821. A confirmed Q4 FY26 earnings recovery in 2026 is the trigger for an initial 10 to 15 percent re-rating from CMP Rs 1,186.

12-Month Tatva Chintan Pharma Chem Share Price Target 2026

The 12-month Tatva Chintan Pharma Chem share price target 2026 is Rs 1,400, implying approximately 20 percent upside from CMP Rs 1,186. This base case assumes in-line FY27 earnings delivery and partial normalisation of FII flows.

Long Term Tatva Chintan Pharma Chem Share Price Target: FY27 to FY28

The long term Tatva Chintan Pharma Chem share price target for FY27 to FY28 is Rs 1,700 in the bull case, requiring full earnings delivery, re-rating among peers in green chemistry like Fine Organic and Aarti Industries, and sustained institutional buying over a 2 to 3 year horizon.

Bull Case and Bear Case Scenarios for Tatva Chintan Pharma Chem in 2026

Bull Case Tatva Chintan Pharma Chem Share Price Target: Rs 1,700

The bull case Tatva Chintan Pharma Chem share price target of Rs 1,700 materialises when FY27 earnings beat analyst estimates, Green Chemistry and Specialty Chemicals tailwinds accelerate, and FII flows return strongly to Indian equities. From CMP Rs 1,186, this represents approximately 45 percent potential upside.

Bear Case Tatva Chintan Pharma Chem Share Price Target: Rs 950

The bear case Tatva Chintan Pharma Chem share price target of Rs 950 materialises if FY27 earnings disappoint or FII outflows depress the broader market, risking a test of support near the 52 week low of Rs 821.

Scenario	Target	Key Conditions
Bull Case	Rs 1,700	FY27 beat, sector re-rating, FII inflows
Base Case (Analyst Target)	Rs 1,400	In-line FY27 delivery, partial FII recovery
Bear Case	Rs 950	FY27 miss, guidance cut, FII outflows persist

Key Risks That Could Derail the Tatva Chintan Pharma Chem 2026 Price Objective

Global Macro and US Tariff Headwinds

Prolonged tariff tensions and global demand slowdown remain prominent macro risks to the Tatva Chintan Pharma Chem share price target of Rs 1,400, with FII outflows being the direct transmission mechanism to Indian equity valuations.

FY27 Earnings Miss and Guidance Risk

An FY27 earnings miss or downward guidance revision would compress valuation multiples and is the most direct company-specific risk to the Rs 1,400 analyst price objective. Investors must monitor quarterly results and management commentary closely.

Competitive Intensity Among Green Chemistry and Specialty Chemicals Peers

Intensifying competition from peers in green chemistry like Fine Organic and Aarti Industries could compress Tatva Chintan Pharma Chem’s market share and pricing power, a structural risk that must be weighed when assessing the defensibility of the earnings trajectory underpinning the Rs 1,400 analyst target for 2026.

Liquidity Risk and FII Selling Pressure

Sustained FII outflows from Indian equities can delay the re-rating process regardless of company-level improvement. Investors should maintain position sizing discipline and stop losses to protect capital.

How to Invest in Tatva Chintan Pharma Chem

Check the Univest Screener for live data

Before considering any investment based on the Tatva Chintan Pharma Chem share price target of Rs 1,400, review Q4 FY26 results and FY27 guidance released in 2026. Focus on revenue growth, margin trends, and management commentary on Green Chemistry and Specialty Chemicals sector demand.

Open a Demat account with a SEBI registered stockbroker to trade Tatva Chintan Pharma Chem (NSE: TATVA) with full regulatory protection. Study the competitive landscape among peers in green chemistry like Fine Organic and Aarti Industries before executing any position.

Plan your entry using the 52 week low of Rs 821 as a key support reference. A confirmed FY27 earnings uptick validates the entry case for the Rs 1,400 price objective. Always set a stop loss below the 52 week low.

Restrict any single stock to 3 to 5 percent of your total equity portfolio. Always consult a SEBI registered financial advisor before investing. SEBI Registration No. INH000013776.

Download the Univest iOS App or the Univest Android App to track Tatva Chintan Pharma Chem’s live share price and receive daily stock recommendations.

FAQs on Tatva Chintan Pharma Chem Share Price Target 2026

What is the Tatva Chintan Pharma Chem share price target for 2026?

Ans. The Tatva Chintan Pharma Chem share price target 2026 is Rs 1,400, implying approximately 20 percent upside from CMP Rs 1,186. Bull case is Rs 1,700, bear case is Rs 950.

What was the Tatva Chintan Pharma Chem share price target for 2025?

Ans. The 2025 price objective for Tatva Chintan Pharma Chem was based on FY26 earnings projections. The current 2026 analyst consensus is Rs 1,400, reflecting FY27 growth potential from CMP Rs 1,186.

Is Tatva Chintan Pharma Chem a good investment at Rs 1,186?

Ans. At Rs 1,186, Tatva Chintan Pharma Chem offers potential upside toward Rs 1,400 if FY27 earnings recover. Whether this represents a good entry depends on individual risk tolerance. Consult a SEBI registered financial advisor before investing.

What are the key risks to the Tatva Chintan Pharma Chem share price target 2026?

Ans. Key risks to the Tatva Chintan Pharma Chem share price target of Rs 1,400 include FY27 earnings miss, global tariff headwinds, FII outflows, and competitive pressure in Green Chemistry and Specialty Chemicals. Monitoring quarterly results is essential.

What is the 52 week high and low of Tatva Chintan Pharma Chem?

Ans. The 52 week high of Tatva Chintan Pharma Chem is Rs 1,946 and the 52 week low is Rs 821. At CMP Rs 1,186, the stock offers potential upside toward the Rs 1,400 price objective.

What are the main growth catalysts for Tatva Chintan Pharma Chem in 2026?

Ans. Key catalysts include FY27 PAT recovery, Green Chemistry and Specialty Chemicals tailwinds, RBI rate cuts in 2026, Budget 2026-27 policy support, and normalisation of FII flows into Indian equities.

How does Tatva Chintan Pharma Chem compare to its peers?

Ans. Tatva Chintan Pharma Chem operates in Green Chemistry and Specialty Chemicals alongside peers in green chemistry like Fine Organic and Aarti Industries. At CMP Rs 1,186 with MCap Rs 2,371 crore, it is a potential re-rating candidate toward the Tatva Chintan Pharma Chem share price target of Rs 1,400 on FY27 delivery.

What is the Tatva Chintan Pharma Chem share price target for 2027?

Ans. The long-term Tatva Chintan Pharma Chem share price target for FY27 to FY28 is Rs 1,700 in the bull case, assuming earnings growth, sector re-rating, and FII inflows. Consult a SEBI registered financial advisor for personalised guidance.